consensus demanding universally available quality health care, greater personal freedom, and the ability to pass on a secure financial legacy to heirs. There is, at the same time, a growing revulsion at the cost and style of our current health and personal insurance systems. The "new genetics" should affirm a broad range of individual rights.
Two publications exist which describe key aspects of the environment in which clinical genetics is currently practiced in this country. One is an article, by Debra S. Stone in Social Research, which outlines social forces shaping the arena in which clinical genetics is now conducted [1] . The other document is a report of the American Council of Life Insurance, authored by Dr. Robert Pokorski [2] . This pamphlet, along with the National Association of Insurance Commissioners Model Regulations, clarifies the positions taken by the life and health insurance industries toward genetic testing and its role in the insurance business. It is extremely important that the public become aware of this stance, as the insurance industry wields tremendous political, economic, and social power.
There are several facts which are not covered in the insurance industry-generated document. There are approximately 30 to 50 million people in this country who do not have adequate health insurance. Indivduals without such health entitlements endure significant suffering in this society, most directly by receiving poor medical care. Insurance in this country (life and/or health) is produced by a collaboration among the private insurance industry, employers, and the government; the state and federal governments help insurers by giving tax considerations to employers for providing group health insurance, through direct payments like Medicaid and Medicare, and, in some venues, through financing state-wide high-risk insurance pools.
Increasingly, employers "self-insure," which means that they themselves provide group health and life insurance, sometimes with the advice or management of representatives of the private insurance industry. This process unites, for practical purposes, the hiring decision with that of insuring.
Insurers, to the extent that they are restrained by law, are regulated at the state level, where they also have significant political influence through lobbyists. Employers' behaviors in pre-employment and other work settings are virtually uncontrolled, except when gross discriminatory activity can be proved, in some federally funded settings, and in states where strict rules control employers' actions. The effect of the recently enacted Americans with Disabilities Act remains uncertain. The effectiveness of regulations designed to retard insurer and employer discrimination is uncertain, especially when economic conditions encourage, and individuals or organizations intend, violations of rules [3] .
It is notable that investors in insurance companies, even during the "genetic revolution" and in the age of human immunodeficiency virus (HIV), still make significant profits and the executives of large insurance companies maintain life styles consistent with the upper classes in our society. Furthermore, this profitable business has been developed with genetic conditions present in the population it serves. The incidence of inherited conditions has not been increasing and will not likely increase in the foreseeable future. Why new detection methods such as DNA-based tests should adversely affect an industry in which premiums are based on known and stable disease occurrence rates is not clear.
In the past, our ignorance about how genes act has often been exceeded by the ignorance of those using genetic information for social, economic, and political purposes [4] . Clinical geneticists sometimes seem content to dismiss past collaborations with the eugenicists as far-off ancient history. Yet in environments where racism is institutionalized and culturally acceptable, there is, even today, a tendency to use the "new genetics" to promote a particular world view under the guise of investigating and applying "scientific fact." For instance, in South Africa, Japan, Singapore, Malaysia, and other countries, genetic information seems to be utilized to justify prejudices and social stratification not inherent in human societies [5] .
Though there have been historical problems in applying genetic findings to benefit humans, there have also been shining successes. In those disorders which have a simple genetic mechanism, many families have been helped by classical and newer approaches. Biochemical assays and prenatal screening have provided significant benefits, though there have also been costs. For example, genetic counseling is not always successful. Clients often remain confused after multiple counseling sessions, a phenomenon which has been documented in several studies [6] . This finding may have to do with the type of service offered, or there may have been selection biases in these studies. Still, miscommunication may result from the nature of the information which clinical geneticists try to impart. There may be important resistances to hearing and understanding hereditary information [7] .
Certainly, my clinical experiences have suggested several "truths" about human genetics. Truth 1. Clinical genetics ispracticed bypeople, biased individuals who make mistakes. Furthermore, the hereditary information that is offered in genetic counseling often suggests that the cause of an illness is known when evidence conceming how genes produce a human pathophysiologicalprocess is actually not available.
Is there evidence that clinical geneticists are fallible? For almost any counseling question (it does not matter what the question is!), a broad range of opinion among counselors from different countries exists on how to deal with a particular genetic issue [8] . This variation indicates that the same basic genetic data differ in importance by context and that an individual counselor's world view and fallibility play a role in delivery of service.
How do we know that genetic causation is misunderstood? Consider the field of behavioral genetics. It has become generally accepted that specific genes determine behavior and psychiatric illnesses, yet the data supporting this hypothesis are generally poor. In fact, the predominance of evidence supports the idea that no simple genetic mechanism controls any behavior or mental condition [9] . Furthermore, in well-studied genetic conditions such as sickle-cell anemia and phenylketonuria (PKU), how hemoglobin S produces illness or phenylalanine causes retarded mental development still remain unclear-despite precise genetic information about these disorders having been available for many years. Truth 2. Clinical geneticists are affected by the economic environment they practice in and are poorly compensated.
My salary is important to me. Clinical geneticists, like other professionals in "cognitive practice," are relatively poorly compensated. Medical geneticists are, in fact, usually financially dependent on lab assays and chargeable procedures, research grants with exorbitant overheads, and, to some extent, state budgets. Clinical geneticists often have to endure ambivalent relations with hospital officials because their specialty does not perform economically, as does cardiology. Medical genetics is not currently listed on the roster of approved specialties maintained by the American Medical Association, which may suggest professional, political, economic, and historical forces inhibiting the growth of clinical genetic practice.
Hospitals are suffering economically as well because they are not being paid for uninsured patients, and compensation for the underinsured, who may require high-cost services, is falling. Many hospitals have responded to this situation by investing in billing procedures which highlight more serious, chronic, disabling disorders for the purpose of deriving better payment from third parties who use diagnostic-related-group (DRG) systems. This process therefore tends to increase the number of individuals who, at one time, have been labeled with economically significant DRG illnesses. Some of these individuals may undeservedly suffer social consequences long after these diagnoses are concocted.
Manifestations of the economic pressures on clinical geneticists are apparent. Clients are defined as "high-risk," which is a statistical, economic, and culturally defined notion, having little to do with their individual personal experience or valuation of a particular condition. For example, women older than 35 years of age, who are pregnant, are often called "high-risk." Likewise, children who are homozygous for the disease alleles at the alpha-1-antitryspin locus are similarly categorized. Yet in both these labeled groups, most individuals will not suffer significant disabilities. More than 90 percent of pregnant women above the age of 35 do not give birth to a disabled child, and more than 90 percent of the children who are homozygous for the alpha-1-antitrypsin disease alleles will not have childhood liver disease. Similarly, non-obedient or "non-compliant" patients can suffer because of appellations that professionals apply.
This use of language to describe clients is important. Earlier in this conference, it was stated that a genetic test "might save a muscle biopsy by diagnosing an illness at the level of the gene." Yet illnesses do not exist in DNA sequences; illness is a disruption in the functioning of an individual and the experience of this change. This type of misuse of language pervades our profession and influences it. Why is it done? In part, it is to garner payment from third parites and to justify the consultations from prepaid physician and health maintenance organizations.
In addition, the current environment encourages health professionals, including medical geneticists, to provide third parties with confidential health information, for billing purposes, which is then codified in insurance company data banks. These computer records of personal information are often maintained without the knowledge of the individuals who are described. The records can be inaccurate. These practices have in the past been critically scrutinized by the federal agencies. Regulators took issue with the handling of this private information and the type of data that were stored. Though modified, the problematic practices continue. Furthermore, photocopies of patients' charts are sent to lawyers, insurers, employers, and other third parties. Put simply, the system as it currently functions alters the way clients are described and frequently violates their right to privacy. Truth 3. Parties other than genetic professionals and affected families are promoting genetic screening.
Certainly, companies producing genetic products have shown interest in promoting and selling new tests. Shortly after the American Society of Human Genetics issued a statement discouraging widespread cystic fibrosis (CF) testing, companies offering DNA tests in Massachusetts began arranging CF testing without genetic counseling for any person who requested it. How effective genetic screening will be in environments influenced by economically weak, unregulated, biotechnology companies remains to be seen.
The insurance industry believes that it has the right to evaluate personal genetic information now and in the future. Insurers currently try to "cream off" high-risk individuals within covered populations through a variety of underwriting practices, an insurance business euphemism for personal investigations. Though insurance industry representatives often state that their companies are not likely to conduct genetic screening now or in the foreseeable future, they demand access to this personal information if it is available at professionals' offices, employment settings, or govermental agencies.
Insurers may use genetic information to make coverages for clients with "highrisk" test results too expensive or limited. Other companies deny coverage, cancel existing policies, or make claims bureaucracies and procedures so unresponsive that insurance benefits are functionally not available. This response can occur as a result of insignificant genetic information. Genetic test results are and will be another factor used to limit individuals' access to necessary entitlements if current social conditions persist.
There is no evidence that individuals identified by HIV testing or new genetic tests so are really going to affect the profitability of insurance companies. This industry fear, termed "adverse risk selection," has not been shown to be economically important at present nor to require a business or regulatory response. Yet insurance companies persist in using the possibility of this phenomenon to justify violating personal rights. In addition, employers seem interested in identifying poorly productive employees, those who may need safer and possibly more costly environments, as well as individuals who may disproportionately consume insurance benefits. Thus, employers and insurers can have similar economic interests in labeling individuals. Also, goverments faced with escalating costs for health care may be interested in categorizing people at "high risk" by supposedly predictive genetic testing. Social planning and "tracking" for educational or budgeting purposes might be the justification for this government effort. Many of the findings noted in this report are indicated by the close examination of 29 cases generated in a survey of genetically based discrimination [10] . This research was conducted using a mailing, advertisements, and personal communications. Most individuals had suffered insurance discrimination in multiple forms. Significant problems in employment settings, with governments, and in negotiating adoptions were also noted.
Finally, there is evidence that therapies for individuals with hereditary disorders are restricted in our society. Families afflicted with PKU are sometimes termed "non-compliant" because they cannot afford the expensive diet. A case in Boston of an individual who needed transplantation surgery and who was denied coverage because he could not prove that his disorder was not a "pre-existing condition" is the ultimate hereditary Catch-22. Expensive gene-based therapies will probably be available only to research subjects, the rich, and the insured in our society.
In conclusion, new DNA-based information is revolutionizing the practice of medical genetics. There are increasing public expectations of this discipline. There is also a changing economic environment that imposes unique pressures on the practice of clinical genetics. New research into our trade is needed so that these pressures can be dealt with reasonably and good counseling delivered.
Many social factors increase the burden suffered by individuals after a genetic diagnosis. These include: designation as "handicapped," "non-compliant," or "highrisk"; limitation of post-test entitlements, including the right to work, to health care, to the financial safety of one's family and other distinctions; associated violations of privacy and other civil rights; residence in a society that tolerates racism or other forms of unfair discrimination; and residence in a society where misconceptions about the importance of gene effects are rampant. These factors all exist in our country today. I believe they could be studied and modified. Finally, practitioners of genetics might play a leading role in lessening society-wide prejudice against those with genetic conditions. The public could be taught that what is considered a genetic trait or disorder has varied with historical time and environment and will continue to do so; genetic variation is the norm in populations; genes do not determine illness nor are the causal mechanisms of illnesses termed "genetic diseases" often understood; variable expression of genes is common, making the positive predictive value of a clinical phenotype after genetic testing uncertain and environmentally dependent; the importance of a genetic variation may require a professional consultation, but the designation of illness must necessarily arise from an interaction between the client, the expert, and the environment in which the client lives.
In summary, to modify an idea drawn from the currently popular pundit, Vaclav Havel, it is hubris for medical geneticists to think that we will someday understand everything. We can continue the struggle for reason, confident in failure and affirming what we know to be right-that genetic information is personal, nondiscriminating, and non-determining, and should remain the individual's confidential personal property.
